511 related articles for article (PubMed ID: 21242742)
1. Cladribine: mode of action and implications for treatment of multiple sclerosis.
Leist TP; Weissert R
Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
[TBL] [Abstract][Full Text] [Related]
2. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
Sipe JC
Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
[TBL] [Abstract][Full Text] [Related]
3. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
[TBL] [Abstract][Full Text] [Related]
4. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
Laugel B; Borlat F; Galibert L; Vicari A; Weissert R; Chvatchko Y; Bruniquel D
J Neuroimmunol; 2011 Dec; 240-241():52-7. PubMed ID: 22035961
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
[TBL] [Abstract][Full Text] [Related]
6. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
7. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
[No Abstract] [Full Text] [Related]
8. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
[TBL] [Abstract][Full Text] [Related]
10. Cladribine for multiple sclerosis: review and current status.
Sipe JC
Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
[TBL] [Abstract][Full Text] [Related]
11. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
Brousil JA; Roberts RJ; Schlein AL
Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Dobosz B; Stelmasiak Z
Acta Neurol Scand; 2004 Jun; 109(6):390-2. PubMed ID: 15147461
[TBL] [Abstract][Full Text] [Related]
13. Oral cladribine and fingolimod for relapsing multiple sclerosis.
Li H; Zhang X
N Engl J Med; 2010 May; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
[No Abstract] [Full Text] [Related]
14. An update on cladribine for relapsing-remitting multiple sclerosis.
Holmøy T; Torkildsen Ø; Myhr KM
Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
[TBL] [Abstract][Full Text] [Related]
15. Cladribine as a therapeutic option in multiple sclerosis.
Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP
Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
[TBL] [Abstract][Full Text] [Related]
16. Cladribine tablets' potential in multiple: sclerosis treatment.
Costello K; Sipe JC
J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
Grieb P; Stelmasiak Z
Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
19. Development of oral cladribine for the treatment of multiple sclerosis.
Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC
J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
[TBL] [Abstract][Full Text] [Related]
20. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
